Genes in panel
Regions in panel
Prev Next

Intellectual disability

Gene: ALKBH8

Amber List (moderate evidence)

ALKBH8 (alkB homolog 8, tRNA methyltransferase)
EnsemblGeneIds (GRCh38): ENSG00000137760
EnsemblGeneIds (GRCh37): ENSG00000137760
OMIM: 613306, Gene2Phenotype
ALKBH8 is in 3 panels

4 reviews

Rebecca Foulger (Genomics England curator)

Comment on list classification: Demoted from Green to Amber based on advice from the Genomics England Clinical Team. In email correspondence, Helen Brittain notes that this is a borderline gene in terms of evidence (two families, 6/7 individuals with seizures and not particularly extensive functional / supportive information). Zornitza's review on the Genetic Epilepsy Syndromes panel focuses on the differing ratings of ALKBH8 on the ID (Green) and Epilepsy (Amber) panels. Based on borderline evidence, I have demoted ALKBH8 to Amber on the ID panel to be consistent with the GLH consensus on the Epilepsy panel (R59 #402).
Created: 19 May 2020, 4:17 p.m. | Last Modified: 19 May 2020, 4:17 p.m.
Panel Version: 3.66

Helen Brittain (Genomics England Curator)

Green List (high evidence)

Two families, different LOF mutations, with evidence of functional impairment of the gene and a relevant phenotype. On this basis I would include it as green, although borderline. This can be reviewed in the light of any new evidence.
Created: 19 Jul 2019, 9:28 a.m. | Last Modified: 19 Jul 2019, 9:28 a.m.
Panel Version: 0.202

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Publications

Catherine Snow (Genomics England)

Comment on list classification: ALKBH8 had been identified by Genomic England curator when article was in press. Requested clinical team for support on rating they advised "there are 7 affected individuals from two families with different LOF variants. They all have ID / GDD. There has been some functional work to indicate a lack of gene function in support. On balance I think this just meets our criteria for a green rating. 6/7 had seizures too so probably worth adding there too."
Created: 24 Jun 2019, 3:48 p.m. | Last Modified: 24 Jun 2019, 3:48 p.m.
Panel Version: 0.193
Expert review by Konstantinos Varvagiannis on ALKBH8. Monies et al. (2019 - PMID: 31079898) report on 7 individuals from 2 different consanguineous Saudi families,
The individuals all had homozygous truncating ALKBH8 pathogenic variants.
All individuals had DD and ID.

ALKBH8 is not currently associated with any phenotype in OMIM / G2P.

Mutations in other genes involved in tRNA modification (eg. ADAT3, PUS3, PUS7) have been shown underlie disorders affecting the CNS, with ID as a feature. ADAT3 is green on ID panel and PUS3, PUS7 have been proposed to included on the ID panel.

ALKBH8 can be included in the ID panel as Amber awaiting further evidence and tagged on the watchlist.
Created: 12 Jun 2019, 2:47 p.m. | Last Modified: 24 Jun 2019, 3:44 p.m.
Panel Version: 0.192

Konstantinos Varvagiannis (Other)

I don't know

Monies et al. (2019 - PMID: 31079898) report on 7 individuals from 2 different consanguineous Saoudi families, harboring homozygous truncating ALKBH8 pathogenic variants. The same individuals are included in another concurrent publication from the same group (Monies et al. 2019 - PMID: 31130284).

All presented with DD and ID (Fam1 : moderate in the proband, degree not commented on for his 3 sibs / Fam2 : mild in the proband, severe in all his 3 sibs). Epilepsy was reported for 6/7 individuals although the type has not been commented on (onset 9-12 months to 2 years). Variable other features were noted in few.

Affected subjects from the first family were homozygous for a stopgain variant (NM_001301010.1:c.1660C>T or p.Arg554Ter) while individuals from the second family were homozygous for a frameshift one (c.1794delC or p.Trp599Glyfs*19). The variants affected in both cases the last exon of ALKBH8 and RT-PCR confirmed that they escape NMD.

Alternative causes were ruled out, at least for the proband from the second family (chromosomal analysis, SNP-array, metabolic investigations).

Linkage analysis of both families confirmed linkage to the same autozygous interval of chr11q22.3 with a LOD score of 6.

Segregation analyses in both families, confirmed homozygosity for the truncating variants in affected members and heterozygosity in their parents (or several unaffected sibs, none of those studied was homozygous for the ref. allele).

In mouse or human cells, ALKBH8 has previously been shown to be involved in tRNA modifications of the wobble uridines of specific tRNAs (PMIDs cited: 20308323, 20583019, 21653555).

LC-MS/MS analyses of tRNA extracted from LCLs derived from affected individuals, unaffected relatives (UR) and independent controls (IC) revealed that wobble nucleotide modifications were completely absent (or dramatically decreased in the case of mcm5U) in affected individuals but readily detected in UR/IC. As specific modifications were absent, substantial amounts of precursors (eg. cm5U - the precursor of mcm5U) were detected in affected individuals but not in unaffected ones.

Absence of wobble modifications (eg. mchm5U) has equally been observed in Alkbh8 knockout mice. Alkbh8-deficient mice show similar increases in precursors. Alkbh8 KO mice are however phenotypically normal (the authors comment that eventual cognitive defects were not formally evaluated and might have been missed - PMIDs cited: 20123966, 21285950).

As a result, the studies carried out confirmed the loss-of-function effect and were in line with previous functional studies in animal models, although the pathogenesis of ID remains unclear.

The expression profile of ALKBH8 is also unclear (wide profile of expression suggested developmentally, the authors studied LCLs, other studies suggest that embryonic expression is broad but becomes progressively more restricted to specific neuronal cells).

Mutations in other genes involved in tRNA modification (eg. ADAT3, PUS3, PUS7) have been shown underlie disorders affecting the CNS, with ID as a feature.

ALKBH8 is not currently associated with any phenotype in OMIM / G2P.

As a result, this gene can be considered for inclusion in the ID/epilepsy panels as amber pending further evidence.
Sources: Literature
Created: 2 Jun 2019, 12:14 p.m.

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Global developmental delay; Intellectual disability; Seizures

Details

Mode of Inheritance
BIALLELIC, autosomal or pseudoautosomal
Sources
  • Expert Review
  • Expert Review
Phenotypes
  • Global developmental delay
  • Seizures
  • Intellectual disability
OMIM
613306
Clinvar variants
Variants in ALKBH8
Penetrance
Complete
Publications
Panels with this gene

History Filter Activity

19 May 2020, Gel status: 2

Entity classified by Genomics England curator

Rebecca Foulger (Genomics England curator)

Gene: alkbh8 has been classified as Amber List (Moderate Evidence).

25 Jul 2019, Gel status: 3

Added New Source, Added New Source, Set Phenotypes, Set publications, Status Update

Catherine Snow (Genomics England)

Source Expert Review Green was added to ALKBH8. Source Expert Review was added to ALKBH8. Added phenotypes Global developmental delay; Seizures; Intellectual disability for gene: ALKBH8 Publications for gene ALKBH8 were changed from 31079898 to 31130284; 31079898 Rating Changed from No List (delete) to Green List (high evidence)

12 Jun 2019, Gel status: 0

Set publications

Catherine Snow (Genomics England)

Publications for gene: ALKBH8 were set to

2 Jun 2019, Gel status: 0

Created, Added New Source, Set mode of inheritance, Set Phenotypes, Set penetrance

Konstantinos Varvagiannis (Other)

gene: ALKBH8 was added gene: ALKBH8 was added to Intellectual disability. Sources: Literature Mode of inheritance for gene: ALKBH8 was set to BIALLELIC, autosomal or pseudoautosomal Phenotypes for gene: ALKBH8 were set to Global developmental delay; Intellectual disability; Seizures Penetrance for gene: ALKBH8 were set to Complete Review for gene: ALKBH8 was set to AMBER